John Overdeck’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-11,130
| Closed | -$43.1K | – | 3570 |
|
|
2024
Q3 | $43.1K | Sell |
11,130
-7,815
| -41% | -$21.6K | ﹤0.01% | 2976 |
|
|
2024
Q2 | $44K | Sell |
18,945
-19,872
| -51% | -$51.3K | ﹤0.01% | 2896 |
|
|
2024
Q1 | $109K | Sell |
38,817
-3,802
| -9% | -$11.3K | ﹤0.01% | 2823 |
|
|
2023
Q4 | $136K | Buy |
+42,619
| New | +$145K | ﹤0.01% | 2908 |
|
|
2021
Q2 | – | Sell |
-10,519
| Closed | -$123K | – | 4679 |
|
|
2021
Q1 | $123K | Buy |
+10,519
| New | +$177K | ﹤0.01% | 3694 |
|
|
2020
Q1 | – | Sell |
-37,288
| Closed | -$849K | – | 3954 |
|
|
2019
Q4 | $849K | Buy |
37,288
+1,130
| +3% | +$16.1K | ﹤0.01% | 2331 |
|
|
2019
Q3 | $517K | Sell |
36,158
-12,677
| -26% | -$186K | ﹤0.01% | 2534 |
|
|
2019
Q2 | $650K | Sell |
48,835
-6,423
| -12% | -$97K | ﹤0.01% | 2296 |
|
|
2019
Q1 | $960K | Buy |
55,258
+4,785
| +9% | +$71.3K | ﹤0.01% | 1857 |
|
|
2018
Q4 | $690K | Sell |
50,473
-3,215
| -6% | -$56.6K | ﹤0.01% | 1891 |
|
|
2018
Q3 | $1.16M | Buy |
53,688
+40,598
| +310% | +$1.23M | ﹤0.01% | 1873 |
|
|
2018
Q2 | $561K | Buy |
+13,090
| New | +$600K | ﹤0.01% | 2572 |
|
|
2018
Q1 | – | Sell |
-4,271
| Closed | -$312K | – | 3596 |
|
|
2017
Q4 | $312K | Buy |
+4,271
| New | +$353K | ﹤0.01% | 2717 |
|
|
2015
Q2 | – | Sell |
-1,143
| Closed | -$563K | – | 3159 |
|
|
2015
Q1 | $563K | Buy |
+1,143
| New | +$443K | ﹤0.01% | 1900 |
|
|
2013
Q3 | – | Sell |
-1,542
| Closed | -$273K | – | 2165 |
|
|
2013
Q2 | $273K | Buy |
+1,542
| New | +$218K | ﹤0.01% | 1674 |
|
John Overdeck's LUMO Position: Q4 2024 in Review
John Overdeck sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q4 2024, closing a stake of 11,130 shares — an estimated $43.1K sold.
John Overdeck first reported a position in LUMO in Q2 2013 and held it in 15 quarters. The position peaked at $1.16M in Q3 2018. 0 funds tracked by Wall St. Rank hold LUMO as of Q4 2024.
- John Overdeck reported no remaining Lumos Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- John Overdeck sold 11,130 Lumos Pharma, Inc. Common Stock shares in Q4 2024, an estimated $43.1K.
- John Overdeck first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
- John Overdeck's Lumos Pharma, Inc. Common Stock position peaked at $1.16M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q4 2024.
Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.